IN8bio, Inc.
INAB
$1.10
-$0.08-6.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.02% | -1.30% | -9.32% | -31.81% | -23.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.11% | -6.96% | -19.14% | -34.33% | -40.14% |
| Operating Income | 5.11% | 6.96% | 19.14% | 34.33% | 40.14% |
| Income Before Tax | 6.14% | 8.29% | 19.77% | 45.61% | 40.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.14% | 8.29% | 19.77% | 45.61% | 40.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.14% | 8.29% | 19.77% | 45.61% | 40.97% |
| EBIT | 5.11% | 6.96% | 19.14% | 34.33% | 40.14% |
| EBITDA | 0.90% | 4.86% | 18.64% | 35.32% | 43.60% |
| EPS Basic | 80.14% | 87.87% | 70.69% | 81.09% | 77.54% |
| Normalized Basic EPS | 80.14% | 87.87% | 70.69% | 77.74% | 77.54% |
| EPS Diluted | 80.14% | 87.87% | 70.69% | 81.09% | 77.54% |
| Normalized Diluted EPS | 80.14% | 87.87% | 70.69% | 77.74% | 77.54% |
| Average Basic Shares Outstanding | 372.59% | 655.92% | 173.69% | 187.67% | 162.87% |
| Average Diluted Shares Outstanding | 372.59% | 655.92% | 173.69% | 187.67% | 162.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |